Cargando…
Comparative study on guidelines in determining HBV phases in Iranian patients
AIM: The aim of this study was to compare the different phases of chronic Hepatitis B virus (HBV) infection with different values for normal ALT. BACKGROUND: For many years, the upper limit of 40 IU was considered normal for ALT for both sexes, but in recent years this value is challenged and some g...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Shaheed Beheshti University of Medical Sciences
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011065/ https://www.ncbi.nlm.nih.gov/pubmed/32099615 |
_version_ | 1783495998959517696 |
---|---|
author | Ashtari, Sara Sharifian, Afsaneh Hatami, Behzad Mohebbi, Seyed Reza Nouri, Gholamreza Bazdar, Monireh Naderi, Nosratollah |
author_facet | Ashtari, Sara Sharifian, Afsaneh Hatami, Behzad Mohebbi, Seyed Reza Nouri, Gholamreza Bazdar, Monireh Naderi, Nosratollah |
author_sort | Ashtari, Sara |
collection | PubMed |
description | AIM: The aim of this study was to compare the different phases of chronic Hepatitis B virus (HBV) infection with different values for normal ALT. BACKGROUND: For many years, the upper limit of 40 IU was considered normal for ALT for both sexes, but in recent years this value is challenged and some guidelines have lowered their limit. METHODS: In this cross-sectional study, 2000 HBsAg positive patients who were referred to Taleghani Hospital, Tehran, Iran, from 2011 through 2018 were classified in four groups according to American Association of the study of the liver disease (AASLD), European Association of the study of the liver (EASL) /Asian-Pacific Association of the study of the liver (APASL) and American Collage of Gastroenterology (ACG) guidelines. The frequency of each group based on 3 different guidelines was compared. RESULTS: In HBeAg positive patients (n=100), the percentage of immune tolerance phase was 43% according to AASLD cutoff for normal ALT (35 IU for men, 25 IU for women), while it was 68% and 28% with regard to EASL/APASL and ACG (30 IU for men, 19 IU for women) cutoffs respectively. In HBeAg negative patients (n=1900), 66.68% were inactive carriers according to AASLD, but the percentage changed to 82.89% and 52.42% considering EASL/APASL and ACG values, respectively. CONCLUSION: Using ACG and to a lesser extent AASLD cutoff for ALT, many patients shift from immune tolerance and inactive carrier state into the immune active phase. Thus, more patients are candidates for treatment or intensive workup to determine the extent of liver damage. |
format | Online Article Text |
id | pubmed-7011065 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Shaheed Beheshti University of Medical Sciences |
record_format | MEDLINE/PubMed |
spelling | pubmed-70110652020-02-25 Comparative study on guidelines in determining HBV phases in Iranian patients Ashtari, Sara Sharifian, Afsaneh Hatami, Behzad Mohebbi, Seyed Reza Nouri, Gholamreza Bazdar, Monireh Naderi, Nosratollah Gastroenterol Hepatol Bed Bench Original Article AIM: The aim of this study was to compare the different phases of chronic Hepatitis B virus (HBV) infection with different values for normal ALT. BACKGROUND: For many years, the upper limit of 40 IU was considered normal for ALT for both sexes, but in recent years this value is challenged and some guidelines have lowered their limit. METHODS: In this cross-sectional study, 2000 HBsAg positive patients who were referred to Taleghani Hospital, Tehran, Iran, from 2011 through 2018 were classified in four groups according to American Association of the study of the liver disease (AASLD), European Association of the study of the liver (EASL) /Asian-Pacific Association of the study of the liver (APASL) and American Collage of Gastroenterology (ACG) guidelines. The frequency of each group based on 3 different guidelines was compared. RESULTS: In HBeAg positive patients (n=100), the percentage of immune tolerance phase was 43% according to AASLD cutoff for normal ALT (35 IU for men, 25 IU for women), while it was 68% and 28% with regard to EASL/APASL and ACG (30 IU for men, 19 IU for women) cutoffs respectively. In HBeAg negative patients (n=1900), 66.68% were inactive carriers according to AASLD, but the percentage changed to 82.89% and 52.42% considering EASL/APASL and ACG values, respectively. CONCLUSION: Using ACG and to a lesser extent AASLD cutoff for ALT, many patients shift from immune tolerance and inactive carrier state into the immune active phase. Thus, more patients are candidates for treatment or intensive workup to determine the extent of liver damage. Shaheed Beheshti University of Medical Sciences 2019 /pmc/articles/PMC7011065/ /pubmed/32099615 Text en ©2019 RIGLD This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Ashtari, Sara Sharifian, Afsaneh Hatami, Behzad Mohebbi, Seyed Reza Nouri, Gholamreza Bazdar, Monireh Naderi, Nosratollah Comparative study on guidelines in determining HBV phases in Iranian patients |
title | Comparative study on guidelines in determining HBV phases in Iranian patients |
title_full | Comparative study on guidelines in determining HBV phases in Iranian patients |
title_fullStr | Comparative study on guidelines in determining HBV phases in Iranian patients |
title_full_unstemmed | Comparative study on guidelines in determining HBV phases in Iranian patients |
title_short | Comparative study on guidelines in determining HBV phases in Iranian patients |
title_sort | comparative study on guidelines in determining hbv phases in iranian patients |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011065/ https://www.ncbi.nlm.nih.gov/pubmed/32099615 |
work_keys_str_mv | AT ashtarisara comparativestudyonguidelinesindetermininghbvphasesiniranianpatients AT sharifianafsaneh comparativestudyonguidelinesindetermininghbvphasesiniranianpatients AT hatamibehzad comparativestudyonguidelinesindetermininghbvphasesiniranianpatients AT mohebbiseyedreza comparativestudyonguidelinesindetermininghbvphasesiniranianpatients AT nourigholamreza comparativestudyonguidelinesindetermininghbvphasesiniranianpatients AT bazdarmonireh comparativestudyonguidelinesindetermininghbvphasesiniranianpatients AT naderinosratollah comparativestudyonguidelinesindetermininghbvphasesiniranianpatients |